U.S. pharma huge copyright scrapped two experimental weight loss drugs past calendar year—a as soon as-everyday pill, lotiglipron, due to elevated liver enzymes along with a twice-day-to-day capsule, danuglipron, as a consequence of strong Uncomfortable side effects—but CEO Albert Bourla has said the company is decided to “play and win” in